CNVs in Epilepsy by unknown
CYTOGENETICS (CL MARTIN, SECTION EDITOR)
CNVs in Epilepsy
Heather C. Mefford
Published online: 28 June 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Copy number variants (CNVs) are deletions or
duplications of DNA. CNVs have been increasingly recog-
nized as an important source of both normal genetic variation
and pathogenic mutation. Technologies for genome-wide
discovery of CNVs facilitate studies of large cohorts of
patients and controls to identify CNVs that cause increased
risk for disease. Over the past 5 years, studies of patients
with epilepsy confirm that both recurrent and non-recurrent
CNVs are an important source of mutation for patients with
various forms of epilepsy. Here, we will review the latest
findings and explore the clinical implications.
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Introduction
Epilepsy is a group of conditions characterized by recur-
rent, unprovoked seizures that result from abnormal syn-
chronized neuronal firing in the brain. Epilepsy will affect
up to 1 in 26 individuals and confers a significant health
and economic burden [1]. There are many forms of epi-
lepsy that can be distinguished by various characteristics
including age of onset, predominant seizure type(s), and
etiology [2]. Three broad classes of epilepsy include
genetic generalized epilepsy (GGE; formerly idiopathic
generalized epilepsy), focal epilepsy, and epileptic
encephalopathy, though it should be noted that there are
many specific epilepsy syndromes within each class
(Table 1).
The causes of epilepsy are diverse. Non-genetic or
acquired etiologies account for 20–30 % of cases and
include stroke, head injury, and tumor. In the remaining
cases, genetics is thought to play a significant role. In fact, it
has been recognized since the time of Hippocrates that
epilepsy is, at least in part, genetic. Modern evidence for
genetic factors comes from twin studies, family studies, and
the identification of single-gene disorders resulting in epi-
lepsy syndromes. Studies in twins show an excess of disease
concordance in monozygotic twins compared to dizygotic
twins for most types of epilepsy. In a large Australian
cohort, generalized epilepsies showed the highest concor-
dance (*80 %); focal epilepsies have a lower (36 %) but
still significant concordance [3]. Family studies reveal that
the overall recurrence risk for epilepsy in first-degree rela-
tives of affected individuals is 2–5 % [4, 5], and at least one
study has shown that there is similar increased recurrence
for family members of probands with either generalized or
focal epilepsy [6]. Finally, large multiplex families in which
epilepsy segregates in an autosomal dominant manner have
been used to identify linkage regions and causative genes in
several different epilepsy syndromes [7].
Despite longstanding knowledge that epilepsy has a
strong genetic component, it was not until 1995 that the
first gene for a form of epilepsy was identified: mutations
in the alpha 4 subunit of the nicotinic acetylcholine
receptor, CHRNA4, were identified in a large family with
autosomal dominant nocturnal frontal lobe epilepsy
(ADNFLE) [8]. Since that time, multiple genes in which
mutations cause epilepsy have been discovered [9, 10].
While many epilepsy genes encode ion channel subunits,
several non-channel genes encoding proteins important for
brain development have been recently discovered as well.
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Copy Number Variants and Human Disease
Copy number variants (CNVs) are large ([1 kb) deletions
or duplications of DNA. CNVs can contain zero, one, or
many genes and have been increasingly recognized as an
important source of both normal genetic variation and
pathogenic mutation. There are two major classes of
CNVs: recurrent and non-recurrent. Recurrent CNVs are
deletions and duplications that occur as a result of non-
allelic homologous recombination (NAHR) at meiosis due
to a predisposing sequence architecture: 50 kb to 10 Mb of
unique DNA flanked by duplicated blocks of sequence that
are [10 kb with [95 % sequence identity [11]. Examples
of recurrent CNVs associated with neurological or neuro-
developmental disorders include duplications of 17p12
causing Charcot–Marie–Tooth type IA [12], deletions of
15q11-q13 in Prader–Willi and Angelman syndromes [13,
14], and deletions of 7q11 causing Williams–Beurens
syndrome [15]. Because of the mechanism by which they
are generated, recurrent CNVs in two unrelated individuals
with the same disorder have nearly identical breakpoints.
Non-recurrent CNVs occur throughout the genome, but
the breakpoints are not consistent. While recurrent CNVs
are generated by aberrant recombination, non-recurrent
CNVs are often due to errors at replication. There are
several mechanisms for the generation of non-recurrent
breakpoints that have been described, many of which
involve microhomology—few to several identical base
pairs at each breakpoint [16]. Non-recurrent CNVs can be
simple, where a stretch of DNA is simply cut out of its
original location and the ends rejoined, or complex, in
which a deletion may be accompanied by insertion or
duplication of DNA at the breakpoints for example. It is
rare to find two or more patients with the same non-
recurrent CNV. However, comparison of overlapping
CNVs in similarly affected patients often reveals a
‘‘smallest region of overlap’’ that can highlight one or a
few genes as primarily responsible for the phenotype.
Examples include the discovery of CHD7 as the gene for
CHARGE syndrome [17], EHMT1 as the critical gene in
9q34 deletions (Kleefstra syndrome) [18], and MBD5 in
2q23.1 deletions [48].
Genome-wide identification of CNVs became efficient
with the introduction of array comparative genomic
hybridization (CGH) and single nucleotide polymorphism
(SNP) microarrays. These technologies allow the detection
of submicroscopic CNVs that are too small to be recog-
nized by routine karyotype analysis. Since the introduction
of these technologies, the rate of discovery of submicro-
scopic rearrangements in both affected and unaffected
individuals has increased dramatically. Early application of
CGH and SNP arrays in control cohorts produced a ‘‘CNV
landscape’’ in unaffected individuals [19–27]. The first
large disease cohorts to be systematically studied were
patients with intellectual disability (ID), followed by aut-
ism and schizophrenia [28, 29]. Comparison of CNVs in
patients to those in controls combined with the identifica-
tion of similar CNVs in multiple affected individuals led to
the discovery of novel, disease-associated CNVs. System-
atic CNV discovery in patients with epilepsy followed, and
there has been steady progress that provides new insight
into the genetics of epilepsy and related disorders. The
remainder of this review will focus on CNV discovery and
characterization in patients with epilepsy and recommen-
dations for clinical testing.
Non-Recurrent CNVs in Epilepsy
The importance of non-recurrent CNVs in epilepsy has
actually been known for some time. For example, tech-
niques such as quantitative PCR and multiplex ligation-
dependent probe amplification (MLPA) have been used to
detect single- and multiple-exon deletions and duplications
in known genes such as SCN1A [30, 31]. However, qPCR
and MLPA are assays directed at specific locations in the
genome, which means CNVs elsewhere will not be
detected.
Real advances in CNV discovery came from the appli-
cation of genome-wide investigations using array CGH or
SNP microarrays. Heinzen and colleagues performed CNV
discovery in a large cohort of 3812 patients with primarily
focal epilepsy syndromes and identified an excess of large
([1 Mb) deletions in affected individuals, the majority of
which were seen in one individual each [32••]. We per-
formed array CGH studies in 517 patients with various
types of epilepsy (primarily generalized); *5 % of
patients carried a non-recurrent CNV that affected at least
one gene and was not seen in controls [33]. In a study of
102 patients with epilepsy with or without other neurode-
velopmental abnormalities, 23/102 individuals had at least
Table 1 Examples of epilepsy syndromes
Major class Examples of specific syndromes
Genetic generalized
epilepsy (GGE)
Juvenile myoclonic epilepsy (JME)
Childhood absence epilepsy (CAE)
Generalized epilepsy with febrile seizures
plus (GEFS?)
Focal epilepsy Temporal lobe epilepsy
Autosomal dominant focal epilepsy with
auditory features (ADPEAF)
Epileptic
encephalopathy
Ohtahara syndrome
Dravet syndrome
West syndrome
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one non-polymorphic CNV [34]. Investigation of patients
with epileptic encephalopathy syndromes also confirms the
role of non-recurrent CNVs in severe epilepsies [35•].
Together, these studies confirm that CNVs are important
contributors to the genetics of broad classes of epilepsy.
Because non-recurrent CNVs are rare and often unique, it
can be difficult to interpret the clinical significance of any
given CNV. Several criteria can be used, including size, gene
content, presence or absence in control studies, and inheri-
tance [36]. While a CNV in a single patient may be difficult to
interpret, by collecting multiple patients with overlapping
non-recurrent CNVs, it becomes possible to determine a
critical region and, sometimes, a single critical gene for a
given condition. This approach has been successful in
highlighting several novel epilepsy genes. For example,
Depienne and colleagues [37] performed array CGH on a
series of patient with a Dravet-like syndrome and identified a
single patient with a deletion involving PCDH19 on chro-
mosome X. Sequence analysis of the gene in additional
patients revealed sequence mutations and established the
gene as a cause of epilepsy restricted to females with ID.
Similarly, rare reports of deletions involving the GRIN2A
gene highlighted the gene as a potentially important gene
[38]. Indeed, we and others have identified mutations in
GRIN2A in 5–20 % of patients with epilepsy syndromes
associated with language deficits (epilepsy aphasia syn-
dromes) [39, 40, 41•]. We recently identified a patient with a
large deletion of 15q26 (reported in [42•] ). Comparing the
deletion in our patient to other 15q26 deletions in the liter-
ature highlighted a single gene in the smallest region of
overlap: CHD2. Using high-throughput targeted sequencing
of CHD2 in 500 patients with epileptic encephalopathy, we
identified de novo pathogenic mutations in 1.2 % of cases
[43]. Additional studies of overlapping rearrangements
published in large disease cohorts, as well as smaller case
reports, are likely to yield important causative genes.
Recurrent Deletions in Epilepsy
A major—and somewhat surprising—advance in the field of
epilepsy genetics has been the discovery of recurrent CNVs
in patients. The importance of recurrent CNVs as causes of
ID syndromes, such as Prader–Willi, Angelman, Smith–
Magenis, and velocardiofacial syndromes, has been known
since the 1980s. More recently, genome-wide CGH in large
cohorts of patients with ID led to the identification of several
novel recurrent microdeletion syndromes [29, 44]. The first
study that highlighted the importance of CNVs in the genetic
etiology of epilepsy was the discovery of recurrent 15q13.3
deletions in patients with generalized epilepsy [45••]. The
15q13.3 microdeletion (chr15: 31,000,000–32,500,000,
hg19) was first described in patients with ID, but it was noted
that most patients also suffered from seizures [46]. This
observation led to a collaborative effort to determine the
frequency of the deletion in a cohort of 1,223 patients with
generalized epilepsy, most of whom did not have ID or other
neurodevelopmental abnormalities. Indeed, 12/1,223 (1 %)
patients carried a 15q13.3 deletion compared to 0/3,699
control individuals [45••]. Several subsequent studies con-
firmed this finding [33, 47, 48], establishing the deletion as
one of the most prevalent genetic risk factors for GGE with
an estimated odds ratio of 68 (29–181) [47].
Two other recurrent deletions have been firmly associ-
ated with epilepsy. De Kovel and colleagues investigated a
cohort of 1,234 individuals with GGE and 3,022 controls
for recurrent CNVs [49]. In addition to 15q13.3 deletions,
they found recurrent deletions at 16p13.11 (chr16:
15,500,000–16,300,000, hg19) and 15q11.2 (chr15:
22,800,000–23,100,000, hg19) in 0.5 and 1 % of patients,
respectively, representing a significantly increased fre-
quency compared to controls. Heinzen and colleagues
performed CNV genotyping in 3,812 individuals with
epilepsy, most of which presented with a focal epilepsy
syndrome [32••]. Deletions of 16p13.11 were also enriched
in patients compared to controls (23/3,812 vs 0/1299).
While 15q11.2 deletions were identified in 24/3,812
patients, there was not a significant enrichment compared
to the frequency in controls (3/1,299). In a study of 517
patients with various types of epilepsy, we identified five
patients each with deletions at 15q11.2, 15q11.3, and
16p13.11, again emphasizing the importance of each of
these as frequent genetic susceptibility factors in epilepsy
[33]. Of note, in an investigation of 315 patients with
epileptic encephalopathy, there were no occurrences of
15q13.3, 16p13.11, or 15q11.2 deletions [35•], suggesting a
different genetic architecture for this class of disorders.
Blurring the Lines: Shared Genetics
of Neurodevelopmental Disorders
Each of the three epilepsy-associated recurrent deletions
must be regarded as a risk factor for disease. In each case,
the deletion may be de novo or inherited from an affected
or unaffected parent. Importantly, all three deletions also
confer risk for other neurodevelopmental disorders. As
described above, deletions of 15q13.3 were first identified
in patients from an ID cohort [46]. The deletion is also
enriched in patients with schizophrenia [50, 51••] and is
seen in patients with autism spectrum disorder and non-
specific developmental delays [52, 53]. Similarly, deletions
of 16p13.11 and 15q11.2 are also associated with a wide
range of neurodevelopmental and neuropsychiatric condi-
tions [32••, 54–57]. Interestingly, the 15q13.3 deletion
appears to confer risk specifically for generalized forms of
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epilepsy—though present in 0.5–1 % of most GGE
cohorts, it was not reported in [3,000 patients with focal
epilepsy syndromes [32••].
Perhaps not surprisingly, patients with one of the epi-
lepsy-associated recurrent deletions may present with a
more severe phenotype than expected. This is especially
true for GGE, which is not typically characterized by other
neurocognitive deficits. Muhle and colleagues [58] identi-
fied 4/570 patients with various types of epilepsy who car-
ried a 15q13.3 deletion. Detailed phenotype analysis
revealed that all patients had absence epilepsy as well as
some degree of ID. Similar features were described in two
other families segregating the 15q13.3 deletion [59]. More
recently, a systematic comparison of the frequency of
recurrent CNVs in patients with GGE compared to patients
with GGE and ID showed that patients with ‘‘dual disabil-
ity’’ are more likely to carry one of the three epilepsy-
associated CNVs than patients with GGE without other
features [42•]: 10 % of the GGE ? ID patients had one of
the three recurrent CNVS compared to *3 % of patients
with GGE but no ID. Other recurrent CNVs that are asso-
ciated with neurodevelopmental disorders are also found in
patients with epilepsy, though not as frequently as the three
deletions discussed above [28, 29, 60]. Examples include
deletions and duplications of 1q21.1, 22q11.2, and 16p11.2.
Who Should be Tested?
The role of CNVs in the genetic etiology of epilepsy has
been clearly established, and diagnostic testing by chro-
mosome microarray should be considered in this popula-
tion. There is a clear consensus that chromosome
microarray testing should be the first-line test in the diag-
nosis of patients with neurodevelopmental disorders or
multiple congenital anomalies [36]. Given the overlapping
genetic etiologies of a broad range of neurodevelopmental
disorders, patients with epilepsy that is associated with
other findings such as ID, autistic features, or develop-
mental delays should be tested. Indeed, for GGE with ID,
the diagnostic yield will be 10 % or greater. Similarly,
patients with brain malformations or other congenital
abnormalities and patients with epileptic encephalopathy
without a clear diagnosis should undergo CNV testing. The
yield of CNV testing in patients with epilepsy and no other
features may be lower, but a CNV involving a known
epilepsy gene would be an important diagnostic finding.
Conclusions
The role of CNVs in the genetic etiology of epilepsy is now
well established. Both recurrent and non-recurrent CNVs
have been identified in most major classes of epilepsy. In
some cases, CNVs are highlighting the shared genetic
susceptibility for a range of neurodevelopmental and neu-
ropsychiatric conditions. It is clear that the identification of
disease-associated CNVs will lead to improved diagnosis
and prognosis counseling. Recurrence risk counseling will
remain complicated for CNVs with broad effects but is
nevertheless an important consideration for families.
Finally, as patients with shared genetic etiologies of epi-
lepsy are identified, studies of genotype–phenotype corre-
lation, natural history, and therapeutic response to specific
anti-epileptic drugs can be performed, which will lead to
improved long-term care and outcomes for patients.
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